Cerenome adds Florida Blue coverage for CNSide tests

Cerenome said it entered an in-network agreement with Florida Blue for CNSide CSF tumor cell enumeration and molecular profile tests, effective Oct 1, 2026, adding about 6M covered lives and bringing contracted access to about 164M commercial and Medicare Advantage lives.